Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Vascepa
NRx (+456)
Generic Vascepa
NRx (+425)
ok 425 does not equal 456 .... but thats not the point
the point is NEW gV Rx's are nearly = to V
I find that disconcerting
gV now = V - this is direct evidence of infringement imho - since 90% of V's market is CAD - how can any thinking judge not view this as infringement is beyond me ....
You know I dont consider myself any form of financial expert but Id like to form a Capital Acquisition COrporation - People give me money to invest I then have an IPO and sell share at $10 but give myself a bunch at $0.005 - sell them off later at near $10 how do you lose at that game ???? Reminds me of JT and crew at AMRN
On August 13, 2020, we issued to our sponsor 5,031,250 founder shares in exchange for a capital contribution of $25,000, or approximately $0.005 per share.
17,500,000 units (or 20,125,000 units if the underwriters’ over-allotment option is exercised in full), at $10.00 per unit, each unit consisting of:
Couldn't agree more ..maybe we can borrow that big red reset button ...
There needs to be a mutifaceted approach to the US
1.) Not one more mention of fish oil
2.) Educate DOcs regarding the distinct difference between dha and epa
3.) Educate Insurers
4.) Educate the public
5.) Launch advertising campaign indicating that if you are not receiving vascepa and have known heart disease your risk of having an event just increased by 25%
I cant emphasize enough how advertising that one sentence would effect Rx numbers !
6.) Institute many more legal actions against insurers / PBM's that allow infringement
7.) They need articles in primary care journals ( Pharmacy Dude if you want to writhe one with me for American Family Physician let me know ).
the list goes on and on
Its not doing much as a stock ....
https://www.google.com/finance/quote/SRSA:NASDAQ?window=5Y
Fascinating IRONWOOD a one product company appointed DEnner ( Dr. Denner is the founding partner and chief investment officer of Sarissa Capital Management LP) to its BOD ....
https://investor.ironwoodpharma.com/press-releases/press-release-details/2020/Ironwood-Pharmaceuticals-Appoints-Alexander-Denner-Ph.D.-to-Board-of-Directors/default.aspx
dont know if anyone posted this
https://www.medscape.com/viewarticle/962972
These are exceptions average premium is about 100% which now would be about $8 https://www.evaluate.com/vantage/articles/news/snippets/biotech-deal-premiums-still-punchy
Not convinced activist investors are going to be the best for a lot of people here - say they came in at $4.xx and force a sale at $8.xx in 6 months - Great return they doubled their money in 6 mos (which also works for me ) but I know there are a lot of people here would be hurt by such an action
$7.40
16% reduction not clinically significant ....
I did a consult for some investors over the weekend on treatment of LDL - it was absolutely amazing - no awareness whatsoever of Vascepa - it was lumped together with Lovaza - their total conversation was on SGLT's and PCSK9's. I repeatedly advised then of REDUCE IT but they seemed rather oblivious - after it all its just "fish oil. "
AMRN's biggest mistake ...allowing the narrative to be managed instead of they managing it ...
All true - I believe the hope was KM would change all of that but I am not seeing it - there seems to be a lack of awareness / vitality / fight call it what you may in the ranks - when I see case after case of infringement and AMRN does nothing to address the situation I find this alarming. They should be calling out every Insurer PBM that is involved in infringement
Agree BBI I indicated I could see a dip to $3.50 - albeit not based on true value as I dont think any investor is counting on COVID success yet there will be a reaction ... and that is another buying opportunity ... no way to lose here - if the news is + great if not I can buy ....
I seem to recall he left many months ago
Have done primary care for 30 years there is absolutely NO WAY I would ever recommend anyone doing this. I use to teach medical students - I began telling them that if they wished to do primary care they should consider it a calling like being a minister or missionary. If they had a personality that allowed them to be used and abused by society - consumed by needy people - then do primary care - otherwise stay away -
Once again you would expect AMRN to be totally aware and managing these issues..
AS I think about this through the years ...say I wanted to sell a widget that I developed . I raised capital hired personnel - took the company public and I am set to go .
Do you think any business person in that scenario would have a total and complete understanding of how to sell that widget ? Afterall you could have the greatest widget in the world but if you cant sell it - what good is it ?
AMRN developed the widget and then went to sell it with no understanding of how to - dismal breakdown of lack of understanding of basic business
They really need to give doctors time just like professors - you work maybe 2- 3 hours a day then you can spend the rest of the day 'keeping up' and then once every five years you get a year off with pay to further "keep up " ....sign me up ....
... and "Business DEvelopment" is vacant .... hmmmm
I like the idea but of course it begs the question why are we doing all of AMRN's work ....
BUt then why wait ? The longer they wait it seems the more leverage they give AMRN is asking for settlement terms ?
hOpe you are correct Pdude but I am not putting any eggs in this basket - my concern is - will failure further damage stock price ? It really should not because I don't think anyone is putting value into Vascepas for this indication but the forces that be will use it to further degrade stock price ...which will be buying time for me. If it fails I fear we might hit $3.50
got it ..thanks ...
Slides says Prepare It 8:15 to 8:20 ...
Amarin (NASDAQ:AMRN) Downgraded by Zacks Investment Research
https://www.marketbeat.com/instant-alerts/nasdaq-amrn-a-buy-or-sell-right-now-2021-11/
Trial by 10/23 ...HIKMA not budging ...unless Rule 60 succeeds we are in the doldrums for some time totally relying on EU to drive value ....
I'm not a lawyer RMB but I agree with Raf - if its IR then its meant to be shared with INvestors
Looks like they have allocated 5 minutes for Prepare-It - I cant imagine groundbreaking news being given only 5 minutes ...
You really expect Doctors and pharmacists to know and understand all of the intricacies of patent law of every medication ...not happening ...first law suit against a doc I guarantee you they all cease writing the rx ...period ..not a great marketing strategy ...
current studies with Vascepa
https://clinicaltrials.gov/search/intervention=amr+101
Send it to IR - yet I can't believe that this is still happening with NO RESPONSE from AMRN no plan - they remain rudderless. We have gone over this so many times - they need a dedicated Insurance sales force
When such occurrences happen
1.) Friendly letter advising company of occurrence
2.) Follow up testing by "unknown customer "
3.) Recurrence ---> legal letter indicating possible legal action
4.) FU visit by unknown customer
5.) Reoccurrence = legal action
COME ON AMRN QUIT ROLLING OVER AND STAND UP FOR WHAT IS RIGHTLY YOURS !
WHY DO WE HAVE TO TALK TO A COMPANY LIKE ITS A 9 YEAR OLD CHILD
Truly embarrassing that non scientist understand the science better than the individuals publishing papers ...unbelievable
AMRN needs to learn to control the narrative - if they are financing this conference in any way they should have stepped forward and said we object to that title please call it EPA etc -- do corporations have a right to respond to microaggressions ? lol
DOtn know if this has been posted
https://www.biospace.com/article/releases/latest-research-evaluating-vascepa-vazkepa-icosapent-ethyl-to-be-presented-at-american-heart-association-scientific-sessions-2021/
why why why ?? !!! Is AMRN letting them call it FISH oil !!! OMG !!!!
Session: Fish Oil, Cocoa, and Cholesterol: Recipes for CVD Prevention?
“Icosapent Ethyl Versus Placebo In Outpatients With Covid-19: The Main Results Of PREPARE-IT 2” – presented on behalf of all authors and the PREPARE-IT 2 Trial Investigators by Rafael Diaz, M.D., Estudios Cardiologicos Latinoamerica (ECLA), Rosario, Argentina – November 15, 2021, 8:00-8:15 am ET
Additional REDUCE-IT® and icosapent ethyl (EPA)-related topics to be presented at AHA Scientific Sessions 2021 can be found here.
Well I guess I missed this low a bit - bought $4.25 guess could have waited for $4.15
Well Ziploc I have been on record stating I dont think its going to work ...but I do hope I am wrong ... I do not factor any COVID into my pricing - so a + result is icing on the cake but even without that AMRN remains a strong buy imho.
When I read this I get the sense that AMRN has no clear strategy or plan to combat the generics - 'its out of their control' They seem clueless as to how to combat the generics - he doesn't seem to understand the process of an MD writing the RX and the pharmacist who fills it being clueless as to the indication its written for
The second one has to do obviously with the situation with the generics because today what we are seeing is that a significant number of patients who are indicated for cardiovascular risk indication, which is an indication not approved for the generic, are still getting the generic. And there are things that we can do as Amarin about this and there are things that are out of our control, let's face it. If the generics continue to supply the market beyond what is needed -- I'm being very clear. Beyond what is needed because the indication size that they have is literally 7% to 8% of the market, but if they continue to push more supply, the payers will use it and we have challenges. That's not in our control. There is a legal sort of path to deal with this. What is in our control is what are we doing to secure the fulfillment of our own prescription.
So what we're really focusing on as a metric is what is the fulfillment rate. How many rejections are we getting? Are we truly getting, at the end of the day, every prescription that is written by a physician, fulfilled at the pharmacist at the end of the day? And that's why we have a number of initiatives to drive this level of fulfillment to be much higher.
So these are really the metrics we're focusing on. I -- it's a difficult question, Roanna, but I hope I clarify.
Make hay when the sun shines plant seeds when it rains ...either way you will be happy ....
Yes it hit my mark as well and I am on record as having bought at $4.25
I didnt get to listen but this does not sound good - do we have a clone of JT ?